research Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
Search
for
Sort by
Research
540-570 / 1000+ results research Efficacy and Safety of Tofacitinib in Lichen Planopilaris: A Retrospective Series of 74 Patients
Tofacitinib may help treat Lichen Planopilaris, but more research is needed.
research Topical application of dehydroxymethylepoxyquinomicin improves allergic inflammation via NF-κB inhibition
A new cream, DHMEQ, reduces allergic skin inflammation effectively.
research Subcutaneous Injection of Large Volumes of Polidocanol
research 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
CTP-543 is generally safe for treating alopecia areata.
research Comparative Evaluation of Oral Baricitinib and Tofacitinib in Alopecia Areata: A Retrospective Cohort Study Based on SALT Scores
Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.
research Anti-androgenetic effect of diphlorethohydroxycarmalol on testosterone-induced hair loss by inhibiting 5α-reductase and promoting Wnt/β-catenin signaling pathway in human dermal papilla cells
Diphlorethohydroxycarmalol may help treat hair loss better than current medications.
research Efficacy of diphenylcyclopropenone in alopecia areata: a comparison of two treatment regimens
Treating alopecia areata every 3 weeks with diphenylcyclopropenone is more effective than weekly treatments.
research Acitretin Loaded Nanocarrier Gel: Formulation and Exploration of In-vitro Release Kinetics
The new gel formulation for Acitretin improves topical delivery and reduces oral toxicity.
research Tofacitinib Treatment in Patients With Active COVID-19 Infection
Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.
research Supplementary file 1_Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients.docx
Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.
research Baricitinib Therapy for Moderate to Severe Alopecia Areata: A Retrospective Review of 95 Japanese Patients
research Social media for arthritis-related comparative effectiveness and safety research and the impact of direct-to-consumer advertising
Social media can help compare the effectiveness and safety of new arthritis medications.
research Dermatologic adverse effect of subcutaneous furosemide administration in a cat
A cat developed skin problems from a certain brand of injected water pills, which went away after switching brands.
research 600 Impact of baricitinib on work productivity and indirect costs in adult patients with atopic dermatitis: A meta-analysis of clinical trials
Baricitinib at 2mg and 4mg doses improved work productivity and reduced costs for adults with atopic dermatitis.
research The manipulation of the cedrol metabolism pathway by baricitinib and its immune interaction mechanism against chemotherapy-induced alopecia
research Supplementary Material for: TOFACITINIB IN OVERLAPPING AUTOIMMUNE AND AUTOINFLAMMATORY DISORDERS: A CASE REPORT OF A DUAL GRAHAM-LITTLE-PICCARDI-LASSEUR SYNDROME AND HIDRADENITIS SUPPURATIVA
Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.
research 170 Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index
Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.
research An urticarial drug eruption caused by tofacitinib for alopecia universalis
A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.
research Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy.
Valproic acid is an effective and safe first-choice treatment for many types of seizures.
research Finasteride
research Finasteride
research Topiramate vs Divalproex Sodium in the Preventive Treatment of Migraine: A Prospective “Real‐World” Study
Both topiramate and divalproex sodium effectively reduce migraine frequency and are generally well-tolerated.
research Central nervous system demyelination associated with tofacitinib use in alopecia areata: A case report and literature review
Tofacitinib may cause nerve damage in the brain, so monitor for neurological symptoms.
research Investigating the synergic effects of valproic acid and crocin on BDNF and GDNF expression in epidermal neural crest stem cells
Valproic acid and crocin together boost cell growth and may help treat nerve injuries.
research Alfuzosin/finasteride
research Alfuzosin/finasteride
research Teriflunomide: A Once-daily Oral Medication for the Treatment of Relapsing Forms of Multiple Sclerosis
Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.
research Betamethasone valerate/minoxidil/tretinoin
The combination of tretinoin, minoxidil, and betamethasone valerate may cause severe scalp inflammation.
research Upadacitinib in concurrent Crohn's disease, atopic dermatitis and alopecia areata: A case report
Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.